CRRTF News and Press, Coronet Carpets Inc From 11/08/23

Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 202...

2023-08-29 08:03:21 ET Crescita Therapeutics ( OTCPK:CRRTF ) Tuesday announced that the Toronto Stock Exchange has approved the company’s proposed normal course issuer bid to purchase up to a maximum of 1,821,616 common shares for cancellation, representing about 10% of its pub...

2023-08-09 12:45:30 ET Crescita Therapeutics press release ( OTCPK:CRRTF ): Q2 GAAP EPS of -C$0.01. Revenue of C$5.2M (-20.1% Y/Y). Segment revenue is expected to be materially lower in the second half of 2023. For further details see: Crescita Therapeutics GAAP ...

Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2023 (&...

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe Canada NewsWire VIENNA , June 1, 2023 /CNW/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliagl...

2023-05-11 13:50:00 ET Crescita Therapeutics press release ( OTCPK:CRRTF ): Q1 GAAP EPS of -C$0.01. Revenue of C$4.6M (-7.1% Y/Y). For further details see: Crescita Therapeutics GAAP EPS of -C$0.01, revenue of C$4.6M

Strong Performance in Commercial Skincare Cash Balance of $10.3M Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company,...

2023-03-15 09:18:02 ET Crescita Therapeutics press release ( OTCPK:CRRTF ): Q4 GAAP EPS of C$0.06. Revenue of C$6M (-20.6% Y/Y). Gross profit was $3,885 compared to $4,651, down $766; Operating expenses were $3,313 compared to $3,536, down $223; Adjusted EBITDA ...

Record Annual Revenue of $23.5M, Up 40% Over F2021 F2022 Adjusted EBITDA 1 of $2.2M, Up 138% Over F2021 Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driv...

Crescita Therapeutics press release ( OTCPK:CRRTF ): Q3 GAAP EPS of C$0.01. Revenue of C$6.03M (+101.7% Y/Y). For further details see: Crescita Therapeutics GAAP EPS of C$0.01, revenue of C$6.03M